140 related articles for article (PubMed ID: 31763620)
1. Molecular Correlates of Socioeconomic Status and Clinical Outcomes Following Hematopoietic Cell Transplantation for Leukemia.
Knight JM; Rizzo JD; Wang T; He N; Logan BR; Spellman SR; Lee SJ; Verneris MR; Arevalo JMG; Cole SW
JNCI Cancer Spectr; 2019 Dec; 3(4):pkz073. PubMed ID: 31763620
[TBL] [Abstract][Full Text] [Related]
2. Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients.
Knight JM; Rizzo JD; Logan BR; Wang T; Arevalo JM; Ma J; Cole SW
Clin Cancer Res; 2016 Jan; 22(1):69-78. PubMed ID: 26286914
[TBL] [Abstract][Full Text] [Related]
3. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
[TBL] [Abstract][Full Text] [Related]
4. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.
Knight JM; Rizzo JD; Hari P; Pasquini MC; Giles KE; D'Souza A; Logan BR; Hamadani M; Chhabra S; Dhakal B; Shah N; Sriram D; Horowitz MM; Cole SW
Blood Adv; 2020 Feb; 4(3):467-476. PubMed ID: 32027744
[TBL] [Abstract][Full Text] [Related]
5. Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis.
Taylor MR; Cole SW; Strom J; Brazauskas R; Baker KS; Phelan R; Buchbinder D; Hamilton B; Schoemans H; Shaw BE; Sharma A; Bhatt NS; Badawy SM; Winestone LE; Preussler JM; Mayo S; Jamani K; Nishihori T; Lee MA; Knight JM
Blood Adv; 2023 Nov; 7(22):6830-6838. PubMed ID: 37773924
[TBL] [Abstract][Full Text] [Related]
6. Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.
Wang Y; Wang T; Dagnall C; Haagenson M; Spellman SR; Hicks B; Jones K; Lee SJ; Savage SA; Gadalla SM
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1054-1058. PubMed ID: 28389255
[TBL] [Abstract][Full Text] [Related]
7. Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia.
Gadalla SM; Wang T; Haagenson M; Spellman SR; Lee SJ; Williams KM; Wong JY; De Vivo I; Savage SA
JAMA; 2015 Feb; 313(6):594-602. PubMed ID: 25668263
[TBL] [Abstract][Full Text] [Related]
8. Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
Segal E; Martens M; Wang HL; Brazauskas R; Weisdorf D; Sandmaier BM; Khoury HJ; de Lima M; Saber W
Cancer; 2017 Sep; 123(17):3346-3355. PubMed ID: 28452054
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
10. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
[TBL] [Abstract][Full Text] [Related]
11. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation.
Kliman D; Nivison-Smith I; Gottlieb D; Hamad N; Kerridge I; Purtill D; Szer J; Ma D
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1711-1718. PubMed ID: 32194285
[TBL] [Abstract][Full Text] [Related]
13. Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia.
Hong S; Rybicki L; Zhang A; Thomas D; Kerr CM; Durrani J; Rainey MA; Mian A; Behera TR; Carraway HE; Nazha A; Mukherjee S; Advani AS; Patel B; Kalaycio M; Bolwell BJ; Hanna R; Gerds AT; Pohlman B; Hamilton BK; Sekeres MA; Majhail NS; Maciejewski JP; Askar M; Sobecks R
Transplant Cell Ther; 2021 Nov; 27(11):917.e1-917.e9. PubMed ID: 34380091
[TBL] [Abstract][Full Text] [Related]
14. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.
Enright H; Davies SM; DeFor T; Shu X; Weisdorf D; Miller W; Ramsay NK; Arthur D; Verfaillie C; Miller J; Kersey J; McGlave P
Blood; 1996 Jul; 88(2):714-20. PubMed ID: 8695820
[TBL] [Abstract][Full Text] [Related]
15. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
[TBL] [Abstract][Full Text] [Related]
16. A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Martus P; Dietz E; Vuong LG; Massenkeil G; Dörken B; Arnold R
Haematologica; 2010 May; 95(5):810-8. PubMed ID: 20007143
[TBL] [Abstract][Full Text] [Related]
17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
18. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation.
Baker KS; Davies SM; Majhail NS; Hassebroek A; Klein JP; Ballen KK; Bigelow CL; Frangoul HA; Hardy CL; Bredeson C; Dehn J; Friedman D; Hahn T; Hale G; Lazarus HM; LeMaistre CF; Loberiza F; Maharaj D; McCarthy P; Setterholm M; Spellman S; Trigg M; Maziarz RT; Switzer G; Lee SJ; Rizzo JD
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1543-54. PubMed ID: 19896078
[TBL] [Abstract][Full Text] [Related]
19. An Examination of Cytomegalovirus, Socioeconomic Status, Race, and Ethnicity on Outcomes after Haploidentical Hematopoietic Transplantation.
Jeurkar C; Leiby B; Banks J; Leader A; Rudolph S; Mateja G; Rashid SA; Carabasi M; Filicko-O'Hara J; O'Hara W; Wagner JL; Gergis U; Flomenberg N; Grosso D
Transplant Cell Ther; 2021 Apr; 27(4):327.e1-327.e11. PubMed ID: 33836876
[TBL] [Abstract][Full Text] [Related]
20. Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes.
Camacho-Bydume C; Wang T; Sees JA; Fernandez-Viña M; Abid MB; Askar M; Beitinjaneh A; Brown V; Castillo P; Chhabra S; Gadalla SM; Hsu JM; Kamoun M; Lazaryan A; Nishihori T; Page K; Schetelig J; Fleischhauer K; Marsh SGE; Paczesny S; Spellman SR; Lee SJ; Hsu KC
Transplant Cell Ther; 2021 Feb; 27(2):142.e1-142.e11. PubMed ID: 33053450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
